Lupin has launched Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base). Lupin’s alliance partner Natco had received an approval from the United States Food and Drug Administration (USFDA) earlier.
Lupin’s Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base), is the generic version of Novartis Pharmaceuticals Corporation’s (Novartis) Gleevec Tablets, 100 mg and 400 mg.
Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base), had annual sales of approximately $548 million in the US (IQVIA MAT May 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
